{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-25-000043","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.659027+00:00","generated_at":"2026-05-28T03:06:40.820196+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cartesian Therapeutics outlines 2025 priorities; Phase 3 MG trial to start in 1H25","bullets":["Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track for 1H25; primary endpoint is MG-ADL improvement ≥3 points at Month 4 vs placebo.","Update Phase 2b MG data: average MG-ADL reduction of 5.5 at Month 4 (n=12); deepening responses over time; no need for preconditioning chemo.","Phase 2 SLE trial of Descartes-08 enrolling; data readout expected in 2H25. SLE affects ~1.5M people in the US.","Descartes-15 Phase 1 dose escalation ongoing in multiple myeloma; after Phase 1, will assess in autoimmune indications.","Cash runway expected to support operations, including completion of Phase 3 MG trial, into mid-2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-25-000043","json":"https://secwatch.observer/filing/0001453687-25-000043.json","markdown":"https://secwatch.observer/filing/0001453687-25-000043.md","text":"https://secwatch.observer/filing/0001453687-25-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000043/0001453687-25-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000043/rnac-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:06:40.820196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}